Navigation Links
Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia

CHATTANOOGA, Tenn., Feb. 14, 2012 /PRNewswire/ -- Glenveigh Medical  announced today that the U.S. Food and Drug Administration (FDA) has granted its request for orphan drug designation for a potential new therapy to treat severe preeclampsia and eclampsia. The compound, digoxin immune fab (ovine), is an existing biologic approved for use in cases of digoxin toxicity. Glenveigh, a nationally renowned life science company, has extensive clinical and in vitro evidence to support continued development of this late-stage opportunity. Preeclampsia occurs in 5-8% of pregnancies in the U.S., and these severe forms are leading causes of maternal and perinatal mortality globally.

"This is a tremendous milestone for our company," stated C. David Adair, M.D., Founder, Chairman, and Chief Scientific Officer of Glenveigh. "As a physician and scientist, I have personally seen the devastation these conditions have caused to both moms and babies.  Our program, which includes two successful Phase II studies, offers hope to patients that there will be a treatment for severe preeclampsia in the near future."

Preeclampsia is a condition in pregnant women that is characterized by high blood pressure and excess protein in the urine in the second and third trimesters of pregnancy. Severe preeclampsia and eclampsia represent the most advanced stages of the disease in which pregnant women can suffer from seizures and organ failure.

"In addition to our patents, orphan designation gives Glenveigh at least 7 years of marketing exclusivity," noted Rick Proctor, President and CEO. "We are delighted that the FDA granted orphan drug designation which gives innovators added incentives to pursue treatments for smaller patient populations."

Eleni Tsigas, Executive Director of the Preeclampsia Foundation, added, "Severe preeclampsia can be life-threatening to mother and baby.  Effective interventions for this serious disorder of pregnancy are lacking. We are thrilled that this designation can better enable further research and development that may lead to a potential therapy."


Glenveigh Medical is a life science and technology based company focused on advancing the practice of obstetrics. Founded in 2004 by a maternal-fetal medicine specialist, Glenveigh prides itself on bringing innovative solutions to the obstetrics industry, relying upon its scientific and medical advisors to provide guidance on market opportunities that will significantly benefit patients in need. Glenveigh's marketed products include the following medical devices: ebb® (post partum hemorrhage), jetty® (vaginal repairs), and Beacon™ (wireless fetal monitor). Glenveigh is based in Chattanooga, Tennessee.

SOURCE Glenveigh Medical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Leading Chemical Weapons Preparedness Companies Announce Partnership to Deploy Break-through Diagnostic Test Internationally
2. Masimo Introduces Pronto-7™ Internationally and Lifts Voluntary Recall
3. Medela Announces 2011 Breastfeeding Hall of Excellence Inductees to Nationally Recognize Exceptional Breastfeeding Advocates
4. Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research
5. Reportlinker Adds Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally
6. Medical Simulation Corporation Signs Agreement With a Nationally Ranked Hospital
7. CORD:USE Cord Blood Bank Featured Internationally on CNN en Espanol
8. Internationally Renowned Bariatric and Laparoscopic Surgeons To Meet in San Diego
9. Lilly Recognized as a Top Company for Executive Women
10. The Lanier Law Firms Dana Taschner Recognized Among Southern Californias Top Lawyers
11. nContacts Corporate Website Recognized as Best in Class Medical Site by Interactive Media Council -
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ( ... as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns ... Dr. Olson says the decision to support the pageant in an official capacity ...
Breaking Medicine News(10 mins):